These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9035229)

  • 21. Differences in adverse drug reactions in phase III and phase IV of the drug evaluation process.
    Linden M
    Psychopharmacol Bull; 1993; 29(1):51-6. PubMed ID: 8378512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk.
    Pompili M; Serafini G; Del Casale A; Rigucci S; Innamorati M; Girardi P; Tatarelli R; Lester D
    Expert Rev Neurother; 2009 Jul; 9(7):985-1004. PubMed ID: 19589049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of antipsychotic drugs and lithium in mania.
    Cookson J
    Br J Psychiatry Suppl; 2001 Jun; 41():s148-56. PubMed ID: 11450176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Are mood stabilizers beneficial in the treatment of schizophrenia?].
    Berle JØ; Spigset O
    Tidsskr Nor Laegeforen; 2005 Jun; 125(13):1809-12. PubMed ID: 16012547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase IV research and drug utilization observation studies.
    Linden M
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):1-3. PubMed ID: 9035221
    [No Abstract]   [Full Text] [Related]  

  • 27. Computerized documentation for lithium outpatients (routine and research data).
    Simhandl C; Thau K; Wolf R; Lenz G; Lovrek A; Wancata J; Topitz A; Denk E
    Pharmacopsychiatry; 1989 Mar; 22(2):76-80. PubMed ID: 2717660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Calcium antagonistic actions of drugs used in treatment of affective disorders].
    Langosch JM; Walden J
    Fortschr Neurol Psychiatr; 1998 Dec; 66(12):570-9. PubMed ID: 9922929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced mortality, the ultimate indicator of treatment efficacy. Review and perspectives.
    Ahrens B
    Pharmacopsychiatry; 1994 Jul; 27 Suppl 1():37-40. PubMed ID: 7984699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychotropic drugs and their relationship with psychopathology of affective disorders.
    Cazzullo CL; Sacchetti E; Smeraldi E
    Prog Neuropsychopharmacol; 1979; 3(1-3):25-38. PubMed ID: 401343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of lithium on suicide and mortality in mood disorders: A systematic review.
    Börjesson J; Gøtzsche PC
    Int J Risk Saf Med; 2019; 30(3):155-166. PubMed ID: 31381531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lithium therapy.
    Dodds G
    Scott Med J; 2000 Dec; 45(6):171-3. PubMed ID: 11216307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Length of lithium treatment needed to eliminate the high mortality of affective disorders.
    Ahrens B; Müller-Oerlinghausen B; Grof P
    Br J Psychiatry Suppl; 1993 Sep; (21):27-9. PubMed ID: 8217064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis.
    Ahrens B; Müller-Oerlinghausen B; Schou M; Wolf T; Alda M; Grof E; Grof P; Lenz G; Simhandl C; Thau K
    J Affect Disord; 1995 Feb; 33(2):67-75. PubMed ID: 7759663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Appraising the quality of drug-evaluation research: II. A methodological review procedure for prophylactic treatment trials.
    King PR
    J Clin Psychopharmacol; 1990 Feb; 10(1):22-6. PubMed ID: 2106532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonpharmacological treatment of affective disorders. Preface.
    Papadimitriou GN; Serretti A
    Neuropsychobiology; 2011; 64(3):127-8. PubMed ID: 21811082
    [No Abstract]   [Full Text] [Related]  

  • 37. Lithium and mortality.
    Gracious KS; Falodun R
    Br J Psychiatry; 2000 Oct; 177():371-2. PubMed ID: 11116785
    [No Abstract]   [Full Text] [Related]  

  • 38. Managing the risk of lithium-induced nephropathy in the long-term treatment of patients with recurrent affective disorders.
    Severus E; Bauer M
    BMC Med; 2013 Feb; 11():34. PubMed ID: 23399409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term lithium and mortality.
    Coppen A; Standish-Barry H; Bailey J; Houston G; Silcocks P; Hermon C
    Lancet; 1990 Jun; 335(8701):1347. PubMed ID: 1971409
    [No Abstract]   [Full Text] [Related]  

  • 40. From the NIH. Consensus statement on 'mood disorders: pharmacologic prevention of recurrences'.
    JAMA; 1984 Sep; 252(10):1264. PubMed ID: 6433050
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.